Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRICAR-ALL
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
TRICAR-ALL is an investigational trivalent chimeric antigen receptor (CAR) T-cell therapy designed to treat B-cell malignancies, specifically Acute Lymphoblastic Leukemia (ALL). The therapy involves genetically modifying a patient's own T cells using a retroviral vector to express a chimeric receptor that simultaneously targets three distinct B-cell antigens: CD19, CD20, and CD22. This multi-antigen targeting strategy is intended to prevent tumor immune escape caused by antigen loss or downregulation, a common cause of relapse in monovalent CAR-T therapies. The CAR construct also incorporates the 4-1BB (CD137) costimulatory domain, which enhances T-cell proliferation, metabolic fitness, and long-term persistence within the patient's body.
- Other names
- CD19/CD20/CD22 CAR-T cellsTrivalent CAR-T cellsCD19/CD20/CD22-4-1BB T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on TRICAR-ALL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRICAR-ALL.